RDY
Dr Reddy's Laboratories Ltd
$14.31
▼ 0.5%Updated Today 12:11 PM ET
RDY at a glance — five pillars scored 0–100 from real filed financials.
Overall: Weak · 39/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▼ Down 5.2% over the last 12 months
Market Cap
$13.76B
P/E
27.33x
Forward P/E (est.)
36.8x
ROE
4.2%
Revenue Growth
3.2%
EPS Growth
-25.7%
Profit Margin
12.4%
FCF Yield
—
Debt / Equity
0.14x
ROIC
—
Interest Coverage
—
Current Ratio
—
Dividend Yield
0.6%
Implied Growth (rev. DCF)
—
Rating Score
39/100
Dr Reddy's Laboratories Ltd (RDY) is a large-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500, with a market value around $13.76B.
Our model rates RDY Weak (39/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what RDY's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. RDY trades near $14.31, above its 50-day average ($13.64) and 200-day average ($13.85). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 62 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. RDY's is $0.41 (~2.9% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month RDY found buyers near $13.08 (support) and sellers near $15.67 (resistance); its 52-week range is $12.19–$15.67. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.1× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
The case for RDY:
- A conservative balance sheet (debt/equity 0.1x) lowers risk.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against RDY:
- Our model's overall read is Weak (39/100).
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Dr Reddy's Laboratories Ltd is a large-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 27.3x earnings, which our model scores Weak (39/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
RDY — frequently asked questions
Is RDY a good stock to buy?
We don't give buy or sell advice. Our model rates Dr Reddy's Laboratories Ltd Weak (39/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is RDY's rating on The Stocks School?
Dr Reddy's Laboratories Ltd currently scores 39/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does RDY's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Dr Reddy's Laboratories Ltd's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for RDY calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this RDY analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell RDY. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.